← Back to patent-cliff list
Soticlestat
Tier C — Watch / tradeSoticlestat
Takeda Pharmaceutical Company Limited
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CYP46A1
Indications (approved)：Lennox-Gastaut syndrome, Dravet syndrome, Seizure, Epilepsy, Hepatic function decline, 染色体重复, 神经发育障碍, 复合性局部疼痛综合征
Regional status
US
Phase III
2021-10-28
EU
Phase III
2021-10-28
China
Phase III
2021-10-28
Japan
Phase III
2021-10-28
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Soticlestat?
Approved indications include: Lennox-Gastaut syndrome, Dravet syndrome, Seizure, Epilepsy, Hepatic function decline, 染色体重复, 神经发育障碍, 复合性局部疼痛综合征.
When does the Soticlestat patent expire?
No public expiry year is available for Soticlestat yet; this page updates once verified.
How do I get a quote for Soticlestat intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06